Cargando…
Rationalized inhibition of mixed lineage kinase 3 and CD70 enhances life span and antitumor efficacy of CD8(+) T cells
BACKGROUND: The mitogen-activated protein kinases (MAPKs) are important for T cell survival and their effector function. Mixed lineage kinase 3 (MLK3) (MAP3K11) is an upstream regulator of MAP kinases and emerging as a potential candidate for targeted cancer therapy; yet, its role in T cell survival...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7410077/ https://www.ncbi.nlm.nih.gov/pubmed/32759234 http://dx.doi.org/10.1136/jitc-2019-000494 |
_version_ | 1783568172359614464 |
---|---|
author | Kumar, Sandeep Singh, Sunil Kumar Viswakarma, Navin Sondarva, Gautam Nair, Rakesh Sathish Sethupathi, Periannan Dorman, Matthew Sinha, Subhash C Hoskins, Kent Thatcher, Gregory Rana, Basabi Rana, Ajay |
author_facet | Kumar, Sandeep Singh, Sunil Kumar Viswakarma, Navin Sondarva, Gautam Nair, Rakesh Sathish Sethupathi, Periannan Dorman, Matthew Sinha, Subhash C Hoskins, Kent Thatcher, Gregory Rana, Basabi Rana, Ajay |
author_sort | Kumar, Sandeep |
collection | PubMed |
description | BACKGROUND: The mitogen-activated protein kinases (MAPKs) are important for T cell survival and their effector function. Mixed lineage kinase 3 (MLK3) (MAP3K11) is an upstream regulator of MAP kinases and emerging as a potential candidate for targeted cancer therapy; yet, its role in T cell survival and effector function is not known. METHODS: T cell phenotypes, apoptosis and intracellular cytokine expressions were analyzed by flow cytometry. The apoptosis-associated gene expressions in CD8(+)CD38(+) T cells were measured using RT(2) PCR array. In vivo effect of combined blockade of MLK3 and CD70 was analyzed in 4T1 tumor model in immunocompetent mice. The serum level of tumor necrosis factor-α (TNFα) was quantified by enzyme-linked immunosorbent assay. RESULTS: We report that genetic loss or pharmacological inhibition of MLK3 induces CD70-TNFα-TNFRSF1a axis-mediated apoptosis in CD8(+) T cells. The genetic loss of MLK3 decreases CD8(+) T cell population, whereas CD4(+) T cells are partially increased under basal condition. Moreover, the loss of MLK3 induces CD70-mediated apoptosis in CD8(+) T cells but not in CD4(+) T cells. Among the activated CD8(+) T cell phenotypes, CD8(+)CD38(+) T cell population shows more than five fold increase in apoptosis due to loss of MLK3, and the expression of TNFRSF1a is significantly higher in CD8(+)CD38(+) T cells. In addition, we observed that CD70 is an upstream regulator of TNFα-TNFRSF1a axis and necessary for induction of apoptosis in CD8(+) T cells. Importantly, blockade of CD70 attenuates apoptosis and enhances effector function of CD8(+) T cells from MLK3(−/−) mice. In immune-competent breast cancer mouse model, pharmacological inhibition of MLK3 along with CD70 increased tumor infiltration of cytotoxic CD8(+) T cells, leading to reduction in tumor burden largely via mitochondrial apoptosis. CONCLUSION: Together, these results demonstrate that MLK3 plays an important role in CD8(+) T cell survival and effector function and MLK3-CD70 axis could serve as a potential target in cancer. |
format | Online Article Text |
id | pubmed-7410077 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-74100772020-08-17 Rationalized inhibition of mixed lineage kinase 3 and CD70 enhances life span and antitumor efficacy of CD8(+) T cells Kumar, Sandeep Singh, Sunil Kumar Viswakarma, Navin Sondarva, Gautam Nair, Rakesh Sathish Sethupathi, Periannan Dorman, Matthew Sinha, Subhash C Hoskins, Kent Thatcher, Gregory Rana, Basabi Rana, Ajay J Immunother Cancer Clinical/Translational Cancer Immunotherapy BACKGROUND: The mitogen-activated protein kinases (MAPKs) are important for T cell survival and their effector function. Mixed lineage kinase 3 (MLK3) (MAP3K11) is an upstream regulator of MAP kinases and emerging as a potential candidate for targeted cancer therapy; yet, its role in T cell survival and effector function is not known. METHODS: T cell phenotypes, apoptosis and intracellular cytokine expressions were analyzed by flow cytometry. The apoptosis-associated gene expressions in CD8(+)CD38(+) T cells were measured using RT(2) PCR array. In vivo effect of combined blockade of MLK3 and CD70 was analyzed in 4T1 tumor model in immunocompetent mice. The serum level of tumor necrosis factor-α (TNFα) was quantified by enzyme-linked immunosorbent assay. RESULTS: We report that genetic loss or pharmacological inhibition of MLK3 induces CD70-TNFα-TNFRSF1a axis-mediated apoptosis in CD8(+) T cells. The genetic loss of MLK3 decreases CD8(+) T cell population, whereas CD4(+) T cells are partially increased under basal condition. Moreover, the loss of MLK3 induces CD70-mediated apoptosis in CD8(+) T cells but not in CD4(+) T cells. Among the activated CD8(+) T cell phenotypes, CD8(+)CD38(+) T cell population shows more than five fold increase in apoptosis due to loss of MLK3, and the expression of TNFRSF1a is significantly higher in CD8(+)CD38(+) T cells. In addition, we observed that CD70 is an upstream regulator of TNFα-TNFRSF1a axis and necessary for induction of apoptosis in CD8(+) T cells. Importantly, blockade of CD70 attenuates apoptosis and enhances effector function of CD8(+) T cells from MLK3(−/−) mice. In immune-competent breast cancer mouse model, pharmacological inhibition of MLK3 along with CD70 increased tumor infiltration of cytotoxic CD8(+) T cells, leading to reduction in tumor burden largely via mitochondrial apoptosis. CONCLUSION: Together, these results demonstrate that MLK3 plays an important role in CD8(+) T cell survival and effector function and MLK3-CD70 axis could serve as a potential target in cancer. BMJ Publishing Group 2020-08-05 /pmc/articles/PMC7410077/ /pubmed/32759234 http://dx.doi.org/10.1136/jitc-2019-000494 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Clinical/Translational Cancer Immunotherapy Kumar, Sandeep Singh, Sunil Kumar Viswakarma, Navin Sondarva, Gautam Nair, Rakesh Sathish Sethupathi, Periannan Dorman, Matthew Sinha, Subhash C Hoskins, Kent Thatcher, Gregory Rana, Basabi Rana, Ajay Rationalized inhibition of mixed lineage kinase 3 and CD70 enhances life span and antitumor efficacy of CD8(+) T cells |
title | Rationalized inhibition of mixed lineage kinase 3 and CD70 enhances life span and antitumor efficacy of CD8(+) T cells |
title_full | Rationalized inhibition of mixed lineage kinase 3 and CD70 enhances life span and antitumor efficacy of CD8(+) T cells |
title_fullStr | Rationalized inhibition of mixed lineage kinase 3 and CD70 enhances life span and antitumor efficacy of CD8(+) T cells |
title_full_unstemmed | Rationalized inhibition of mixed lineage kinase 3 and CD70 enhances life span and antitumor efficacy of CD8(+) T cells |
title_short | Rationalized inhibition of mixed lineage kinase 3 and CD70 enhances life span and antitumor efficacy of CD8(+) T cells |
title_sort | rationalized inhibition of mixed lineage kinase 3 and cd70 enhances life span and antitumor efficacy of cd8(+) t cells |
topic | Clinical/Translational Cancer Immunotherapy |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7410077/ https://www.ncbi.nlm.nih.gov/pubmed/32759234 http://dx.doi.org/10.1136/jitc-2019-000494 |
work_keys_str_mv | AT kumarsandeep rationalizedinhibitionofmixedlineagekinase3andcd70enhanceslifespanandantitumorefficacyofcd8tcells AT singhsunilkumar rationalizedinhibitionofmixedlineagekinase3andcd70enhanceslifespanandantitumorefficacyofcd8tcells AT viswakarmanavin rationalizedinhibitionofmixedlineagekinase3andcd70enhanceslifespanandantitumorefficacyofcd8tcells AT sondarvagautam rationalizedinhibitionofmixedlineagekinase3andcd70enhanceslifespanandantitumorefficacyofcd8tcells AT nairrakeshsathish rationalizedinhibitionofmixedlineagekinase3andcd70enhanceslifespanandantitumorefficacyofcd8tcells AT sethupathiperiannan rationalizedinhibitionofmixedlineagekinase3andcd70enhanceslifespanandantitumorefficacyofcd8tcells AT dormanmatthew rationalizedinhibitionofmixedlineagekinase3andcd70enhanceslifespanandantitumorefficacyofcd8tcells AT sinhasubhashc rationalizedinhibitionofmixedlineagekinase3andcd70enhanceslifespanandantitumorefficacyofcd8tcells AT hoskinskent rationalizedinhibitionofmixedlineagekinase3andcd70enhanceslifespanandantitumorefficacyofcd8tcells AT thatchergregory rationalizedinhibitionofmixedlineagekinase3andcd70enhanceslifespanandantitumorefficacyofcd8tcells AT ranabasabi rationalizedinhibitionofmixedlineagekinase3andcd70enhanceslifespanandantitumorefficacyofcd8tcells AT ranaajay rationalizedinhibitionofmixedlineagekinase3andcd70enhanceslifespanandantitumorefficacyofcd8tcells |